Show simple item record

dc.contributor.authorOharte, FPM
dc.contributor.authorParthsarathy, Vadivel
dc.contributor.authorHogg, C
dc.contributor.authorFlatt, P
dc.date.accessioned2020-04-01T15:10:56Z
dc.date.available2020-04-01T15:10:56Z
dc.date.issued2018-08-29
dc.identifier.citationO'Harte, F., V, P., Hogg, C., & Flatt, PR. (2018). 'Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice'. PLoS ONE, 13(8), pp. 1-17.en_US
dc.identifier.issn1932-6203
dc.identifier.pmid30157220
dc.identifier.doi10.1371/journal.pone.0202350
dc.identifier.urihttp://hdl.handle.net/10545/624642
dc.description.abstractPrevious studies have shown that modified apelin analogues exhibited enzyme resistance in plasma and improved circulating half-life compared to apelin-13. This study investigated the antidiabetic effects of chronic administration of stable long acting fatty acid modified apelin analogues, namely, (Lys8GluPAL)apelin-13 amide and pGlu(Lys8GluPAL)apelin-13 amide, in high-fat fed obese-diabetic mice. Male NIH Swiss mice (groups n = 8) were maintained either on a high-fat diet (45% fat) from 8 to 28 weeks old, or control mice were fed a normal diet (10% fat). When diet induced obesity-diabetes was established after high-fat feeding, mice were injected i.p. once daily with apelin analogues, liraglutide (25 nmol/kg) or saline (controls). Administration of (Lys8GluPAL)apelin-13 amide and pGlu(Lys8GluPAL)apelin-13 amide for 28 days significantly reduced food intake and decreased body weight. Non-fasting glucose was reduced (p<0.01 to p<0.001) and plasma insulin concentrations increased (p<0.01 to p<0.001). This was accompanied by enhanced insulin responses (p<0.01 to p<0.001) and significant reductions in glucose excursion after oral (p<0.01) or i.p. (p<0.01) glucose challenges and feeding. Apelin analogues also significantly improved HbA1c (p<0.01), enhanced insulin sensitivity (p<0.01), reduced triglycerides (p<0.001), increased HDL-cholesterol (p<0.01) and decreased LDL-cholesterol (p<0.01), compared to high-fat fed saline treated control mice. Cholesterol levels were decreased (p<0.01) by pGlu(Lys8GluPAL)apelin-13 amide and both apelin treated groups showed improved bone mineral content, reduced fat deposits and increased plasma GLP-1. Daily treatment with liraglutide mirrored many of these changes (not on bone or adipose tissue), but unlike apelin analogues increased plasma amylase. Consumption of O2, production of CO2, respiratory exchange ratio and energy expenditure were improved by apelin analogues. These results indicate that long-term treatment with acylated analogues (Lys8GluPAL)apelin-13 amide and particularly pGlu(Lys8GluPAL)apelin-13 amide resulted in similar or enhanced therapeutic responses to liraglutide in high-fat fed mice. Fatty acid derived apelin analogues represent a new and exciting development in the treatment of obesity-diabetes.en_US
dc.description.sponsorshipThe Department for the Economy, Northern Ireland (https://www.nidirect.gov.uk/articles/department-economy-studentships, formerly DEL-NI) provided a PhD studentship to CH and FOH to perform this work. Invest-NI Proof of Concept funding (https://www.investni.com/support-for-business/proof-of-concept.html, PoC518) was secured by FOH and PRF.en_US
dc.language.isoenen_US
dc.publisherPLoSen_US
dc.relation.urlhttps://pure.ulster.ac.uk/en/publications/long-term-treatment-with-acylated-analogues-of-apelin-13-amide-amen_US
dc.relation.urlhttps://journals.plos.org/plosone/article/file?type=printable&id=10.1371/journal.pone.0202350en_US
dc.rightsCC0 1.0 Universal*
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.subjectapelin-13, T2DM, Obesityen_US
dc.titleLong-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice.en_US
dc.typeArticleen_US
dc.contributor.departmentUlster Universityen_US
dc.identifier.journalPLoS ONEen_US
dc.source.journaltitlePloS one
dcterms.dateAccepted2018-08-01
refterms.dateFOA2020-04-01T15:10:56Z
dc.author.detail785773en_US


Files in this item

Thumbnail
Name:
Finbarr et al 2018.pdf
Size:
4.887Mb
Format:
PDF
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record

CC0 1.0 Universal
Except where otherwise noted, this item's license is described as CC0 1.0 Universal